Artelo Biosciences' SBFI103 shows anxiolytic and antidepressant effects in preclinical model.

Artelo Biosciences has announced the publication of new research demonstrating that its proprietary FABP5 inhibitor SBFI103 produces anxiolytic and antidepressant-like effects in a preclinical model of chronic stress when administered intraperitoneally. The study was partially funded by the company and was conducted in collaboration with Dr. Steven Laviolette of the University of Western Ontario. The findings have the potential to inform the development of treatments for anxiety and depression.